Fortis Life Sciences®, a global leader in reagent and service solutions for life sciences and diagnostics, has added two seasoned executives to its senior leadership team. Darcy Birse has been appointed General Manager of the Antibody Solutions Business Unit, and Emily Moran has been appointed General Manager of the Cell & Gene Therapy Solutions Business Unit. 

“We are pleased to welcome Darcy and Emily to Fortis,” said Dave King, CEO of Fortis Life Sciences. “Their exceptional leadership, strategic insight, and extensive industry expertise will further enhance our capabilities, empowering us to deliver cutting-edge, high-quality solutions to our life sciences and diagnostics customers across the globe.”

Darcy Birse – General Manager, Antibody Solutions
Darcy will lead the Antibody Solutions business, which includes the Bethyl Laboratories, Abcore, and Arista Biologicals brands. As General Manager, Darcy will drive growth and innovation across the antibody portfolio to support customer applications, including drug discovery, spatial biology, and immunodiagnostics.

Darcy was most recently CEO of Culture Biosciences. Prior to that, he served as CCO at Cell Signaling Technology (CST), and before that, held executive roles at GE Healthcare Life Sciences and Lonza Pharma. Darcy holds a BSc in Chemistry from Dalhousie University, earned a D.E.A. in Structural Biology in Strasbourg, France, obtained a PhD in Physics from Joseph Fourier University/EMBL in Grenoble, France, and completed his EMBO post-doctoral research in Biochemistry at Stockholm University, Sweden. 

“I am thrilled to join Fortis Life Sciences and bring together technology and innovation to best serve our customers and improve healthcare outcomes,” added Mr. Birse. 

Emily Moran – General Manager, Cell & Gene Therapy Solutions 

Emily Moran will oversee the Cell & Gene Therapy Solutions business, including its flagship brand, Vector Biolabs. In her role, Emily will focus on delivering innovative viral R&D solutions and high-quality reagents to support critical advancements in cell and gene therapy.

Emily most recently served as SVP, Manufacturing and MS&T for Cell, Viral, and Plasmid Manufacturing at SK Pharmteco, formerly the Center for Breakthrough Medicines. Prior to that, Emily served as Head of Viral Vector Manufacturing at Lonza and across multiple operational and quality roles at Sanofi. She has a BS in Biology from Ursinus College and an MBA in Project Management from the New York Institute of Technology. 

Ms. Moran added, “I am truly excited to join Fortis Life Sciences and contribute to delivering exceptional products and services that drive progress and accelerate breakthroughs in cell and gene therapy drug discovery—and beyond.”